Cordis’s SELUTION SLR Drug-Eluting Balloon (DEB) features unique MicroReservoirs that encapsulate and protect sirolimus, facilitating a sustained and consistent drug release into the vessel wall. This technology, combined with Cell Adherent Technology (CAT), ensures efficient drug uptake and retention, minimizing drug loss during the procedure. The balloon is designed for both coronary and peripheral artery disease, offering a broader portfolio of treatment options. 

Feature

• MicroReservoirs:

  These are microscopic reservoirs embedded within the balloon’s coating. They contain sirolimus and a biodegradable polymer (PLGA), acting as a controlled-release delivery system. 

   
• Cell Adherent Technology (CAT):

  CAT helps the micro-deposits adhere to the vessel wall, enhancing drug retention and minimizing drug loss during inflation. 

   
• Sustained Drug Release:

  The MicroReservoirs enable a sustained release of sirolimus for up to 90 days, mimicking the drug release profile of drug-eluting stents. 

   
• Drug:

  The balloon is coated with sirolimus, an anti-proliferative drug, which helps prevent restenosis (re-narrowing of the artery). 

   
• Indications:

  The SELUTION SLR DEB is indicated for treating both coronary artery disease (including in-stent restenosis and de novo lesions) and peripheral artery disease (such as SFA and BTK).